Archivel's RUTI®, a novel therapeutic vaccine to Latent Tuberculosis, starts phase II clinical trials in South Africa

Archivel's RUTI®, a novel therapeutic vaccine to Latent Tuberculosis, starts phase II clinical trials in South Africa

 
The double-blind, randomized, placebo-controlled phase II clinical trial is designed to investigate the safety, tolerability and immunogenicity of the antituberculosis vaccine RUTI in subjects with latent tuberculosis infection
 
Archivel will provide vaccine RUTI from its recently certified GMP manufacturing plant in Badalona, Catalonia, Spain
 
The therapeutic vaccine has potential to significantly reduce the time required for the current antibiotic treatments, one of the unmet needs identified in the fight against tuberculosis worldwide
 
BIO Convention, Chicago, Il - 5 May 2010.  Archivel Farma, a biotechnological company focused on the discovery and development of new immunomodulating biopharmaceutical agents to prevent and treat tuberculosis and other diseases, announced today that the Medicinal Control Council of the Republic of South Africa approved on April 22 the start of the first clinical trial of the therapeutic vaccine RUTI in latent tuberculosis infection (LTBI).
 
The trial will be run in 3 centers and will enrol 96 individuals with or without concomitant HIV infection. The primary goal is to evaluate the safety, tolerability and immunogenicity of the vaccine RUTI -- Archivel's proprietary therapeutic vaccine made with detoxified cellular fragments from Mycobacterium tuberculosis, the causal agent of tuberculosis. Primary results are expected by year's end.
 
The therapeutic vaccine has already been tested in a double blind, randomized, placebo-controlled Phase I Clinical trial with 24 healthy volunteers performed in a single site in Catalonia, Spain. The results, published in the January 22 2010 issue of the peer-reviewed journal Vaccine, demonstrated that the vaccine RUTI is safe, well tolerated and immunogenic, and helped defining the appropriate dosing and regime to be explored in the current phase II trial.
 
Archivel will manufacture and deliver the vaccine RUTI from its own manufacturing facilities, located in Badalona, close to Barcelona in Catalonia, Spain. The plant obtained the Spanish GMP certification in March 2010. It has a built-in P3 lab that enables the culture and processing of the tuberculosis bacillus (and other pathogenic agents) in order to produce the final sterile, lyophilized preparation that does not require any adjuvants. 
 

Further information on Archivel at www.archivelfarma.com
Archivel Farma S.L., 61 c/ Fogars de Tordera, Polígon Industrial Bonavista, 08916 BADALONA, Spain.  Tel +34 93 497 2456./ +34 637 057432  [email protected] 

Press information and illustrations
Nigel Robson, Vortex PR, Island House, Forest Road, Forest, Guernsey GY8 0AB, UK.  Tel +44 (0) 1481 233080  [email protected]

 

RUTI is a registered trademark of Archivel Farma S.L. all other trademarks are the property of their respective owners.

 


If you wish to be removed from this mailing list, please contact [email protected]

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.